Methylphenidate is the first-choice pharmaceutical treatment for children and adolescents with attention deficit/hyperactivity disorder (ADHD). Concerns have been raised regarding unnecessary or suboptimal prescription of this medicine. Based on the results of three recently conducted Dutch studies – the Medication Optimization for ADHD study (MOVA), the Methylphenidate Discontinuation Study in Children (MASK), and the Discontinuation Trials Study – we advocate for an evidence-based approach to…
